Nirsevimab, a monoclonal antibody, is highly effective in real-world conditions at preventing severe respiratory syncytial ...

Germany's Robert Koch Institute (RKI) for infectious diseases has declared the country's RSV wave officially over. RSV, or ...

Each year, approximately 177,000 adults aged 65 and older are hospitalized in the United States due to RSV, and an estimated ...

The seasonal timing of when infants receive the new respiratory syncytial virus (RSV) immunization is crucial for ensuring ...

"Nirsevimab is highly effective in preventing RSV-related outcomes in infants, with a pooled real-world effectiveness of 83 ...

A phase 3 trial involving nearly 25,000 older adults across 17 countries found that a single dose of the RSVPreF3 OA vaccine ...

The FDA is expected to decide on treatments for bullous pemphigoid, hereditary angioedema, HIV PrEP, ovarian cancer, and RSV.

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

Action News anchor Vanessa Vasconcelos sat down with Emergency Physician Doctor Rais Vohra to talk about viruses like the Flu ...

Vulnerable Australians aged 50-59 will be able to receive a vaccine for respiratory syncytial virus (RSV).